AMGEN, INC. for AMGEN INC

Taxation/Internal Revenue Code TAX

International Tax issues including regarding Public Law 115-97, Tax Cuts and Jobs Act Tax issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income

Contacted: Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS); Natl Economic Council (NEC)

Copyright/Patent/Trademark CPT

S. 124 Preserve Access to Affordable Generics Act Issues related to drug patents and exclusivities (no bill) H.R. 1520, Purple Book Continuity Act of 2019 H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 S. 1224, The Stop STALLING Act S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing S.659 - the Biologics Patent Transparency Act H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act

Contacted: SENATE; Natl Economic Council (NEC); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 2375 (116th), S. 659 (116th), H.R. 1499 (116th), H.R. 5133 (116th), S. 1416 (116th), S. 124 (116th), H.R. 938 (116th), H.R. 1520 (116th), S. 1224 (116th), H.R. 3991 (116th), H.R. 2374 (116th)

Health Issues HCR

Biosimilars, no specific bill Prescription drug value issues, no specific bill FDA issues, no specific bill Issues related to International Pricing Index (IPI), no specific bill S. 657 Drug Price Transparency Act S. 658 Accelerated Drug Approval for Prescription Therapies Act S. 660 Efficiency and Transparency in Petitions Act S. 1895, Lower Health Care Costs Act, a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs H.R. 1499, Protecting Consumer Access Generic Drugs Act H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act S. 1169, Ensuring Timely Access to Generics Act S. 1617, Second Look at Drug Patents Act H.R. 1520, Purple Book Continuity Act S. 977, Transparent Drug Pricing Act S. 102, Prescription Drug Price Relief Act S. 659, Biologic Patent Transparency Act H.R. 1503, Orange Book Transparency Act H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act S. 1664, Prescription Drug Price Reporting Act S.659 - the Biologics Patent Transparency Act Supply Chain Issues, no specific bill

Contacted: Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: S. 1664 (116th), H.R. 1503 (116th), H.R. 1344 (116th), S. 1895 (116th), S. 659 (116th), S. 660 (116th), H.R. 2296 (116th), S. 657 (116th), H.R. 1520 (116th), S. 102 (116th), S. 977 (116th), S. 1617 (116th), S. 658 (116th), H.R. 1499 (116th), S. 1169 (116th)

Medicare/Medicaid MMM

Medicare Part B coverage and reimbursement issues Issues related to International Pricing Index (IPI), no specific bill Coding and reimbursement for biologics/biosimilars Issues related to Part D redesign, no specific bill Issues related to Part D rebate reform, no specific bill Medicare Part D access issues for plan year 2020, no specific bill S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues H.R. 2296/S 1391 FAIR Drug Pricing Act S. 1416 Affordable Prescriptions for Patients Act Issues related to Direct to Consumer Advertisement Issues related to Biosimilars, no specific bill Prescription drug value issues, no specific bill S. 1664, Prescription Drug Price Reporting Act H.R. 3 - Lower Prescription Drug Costs Now Act H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019 Issues related to the Center for Medicare & Medicaid Innovation S. 2543 Prescription Drug Pricing Reduction Act Section 210- Applying Medicaid Drug Rebate Requirement to Drugs Provided as Part of Outpatient Hospital Services H.R. 19/S. 3129 Lower Costs, More Cures Act 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and cost-sharing assistance. HR 748 Coronavirus Aid, Relief, and Economic Security (CARES) Act and access to Part B medicines at home Issues related to the 340B program, no specific bill

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); SENATE; Commerce, Dept of (DOC)

Bills named: H.R. 2296 (116th), S. 3129 (116th), H.R. 19 (116th), S. 283 (116th), S. 1664 (116th), S. 1416 (116th), H.R. 748 (116th), H.R. 2693 (116th), S. 1676 (116th), H.R. 3 (116th), S. 2543 (116th)